BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology ...
The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...
The subcutaneous administration of the established immunotherapy could free up an estimated 30,000 hours of infusion chair ...
A modified immunotherapy regimen for advanced melanoma showed a 49% response rate and extended median overall survival to 42 ...
Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is indicated for the treatment of adult and paediatric patients 12 years and older with unresectable or metastatic microsatellite ...
In a significant regulatory development for cancer care in India, the Subject Expert Committee functioning under the Central ...
Barchart on MSN
Is Bristol-Myers Stock Underperforming the S&P 500?
New Jersey-based Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical giant focused on discovering, developing and delivering innovative medicines for serious diseases, with core areas ...
Zacks Investment Research on MSN
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Bristol Myers BMY has a robust oncology portfolio, including the blockbuster immune-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others. Opdivo is a key drug in BMY’s growth portfolio that ...
Opdivo showed superior long-term efficacy over Yervoy in resected stage 3B-4 melanoma, with improved RFS and DMFS outcomes. Median OS and MSS were not reached, but data favored Opdivo, suggesting a ...
TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback